#compounding
12 pieces tagged compounding.
- The moleculesSermorelin, tesamorelin, ipamorelin and CJC-1295 comparedThree of these are GHRH analogues; ipamorelin is a five-residue ghrelin-receptor ligand. One had an approved product that was discontinued, one has an approved product on the market, two have none. Identity and status side by side.
- The moleculesSemax and Selank: two heptapeptides and their US statusSemax (MEHFPGP) is four residues of ACTH plus a Pro-Gly-Pro tail; Selank (TKPRPGP) is the tetrapeptide tuftsin plus the same tail. Where each came from, what the spelling variants mean, and their status as of September 2026.
- The moleculesNAD+, 5-amino-1MQ and glutathione: which are peptides?Three catalog staples that share a shelf with peptides. Only one is a peptide. What each molecule actually is, from PubChem, and why the distinction changes what a certificate should show.
- The moleculesMelanotan II, PT-141 and afamelanotide: one parent, three analoguesAfamelanotide, Melanotan II and bremelanotide all descend from the 13-residue hormone alpha-MSH. Two became approved drugs; Melanotan II never did. Structures, lineage, FDA's own words on MT-II, and status as of September 2026.
- The moleculesGHK-Cu: why the powder is blue and what copper peptide meansGHK-Cu is the tripeptide glycyl-histidyl-lysine holding one copper(II) ion. The copper is what makes it blue, what makes it a different molecule from GHK, and what its two INCI names are about. Status as of September 2026.
- Where the line isApproved, investigational, or neither: a status table for 27 peptidesOne table, three statuses. Which peptides have an FDA-approved product, which are in a sponsor's trial program, and which have neither, with the compounding category and WADA line for each, as of September 21, 2026.
- The moleculesEpithalon, epitalon and the word bioregulatorOne tetrapeptide, four spellings, and a term that is not a pharmacological class. What AEDG is, where it came from, what the Khavinson school means by bioregulator, and its US status as of September 21, 2026.
- Where the line isWhat ended for compounded semaglutide and tirzepatide, and whenCompounded tirzepatide and semaglutide were allowed only while the approved products were in shortage. The shortages and grace periods ended in 2024 and 2025. What is still open, and why a research vial is no substitute.
- Where the line isCategory 1, Category 2 and the 503A bulks list in 2026Twelve peptides left FDA's Category 2 in April, GHK-Cu went back into Category 1 in May, and an advisory committee voted in July. None of it put a peptide on the 503A bulks list. A dated tracker.
- Where the line isBPC-157 in 2026: not banned, not approved, not compoundableThree separate questions get asked as one. BPC-157 is not a controlled substance, is not an FDA-approved drug, and has no lawful 503A compounding pathway. What the molecule is and where each answer comes from, dated.
- Where the line isAre peptides legal in the United States? A dated answer"Legal" hides seven different questions: controlled-substance status, who the law regulates, sale as research material, approval, compounding, import and sport. Each has a different answer and a different regulator. Here they are, dated.
- Where the line isCompounding pharmacy, outsourcing facility or research supplierA 503A pharmacy, a 503B outsourcing facility and a research supplier operate under three different sets of rules. What each one is, why a pharmacy cannot compound BPC-157 today, and why a research vial has no place in the other two chains.
Nothing here is medical advice. Everything on this site is supplied for laboratory research use only.